A new enzyme can break down 99% of the gluten that triggers celiac disease—before it reaches the small intestine. Called celiacase, the enzyme targets the protein fragments that cause intestinal damage in celiac patients. Published in EMBO Molecular Medicine, the findings mark important progress toward treatments that could make the gluten-free diet easier to follow.
What This Means for You
As the parent of a child with celiac disease, I’ve followed enzyme research for years with cautious interest. The gluten-free diet works, but it’s exhausting—every meal requires vigilance, social events become minefields, and the risk of accidental exposure is always there.
This enzyme works in your stomach, breaking down gluten before it reaches your small intestine where it causes damage. In lab tests, it destroyed 99% of the harmful gluten fragments. That’s not a cure, but it could provide protection against accidental exposure—the cross-contact at restaurants, the mislabeled products, the well-meaning relatives who don’t understand that “just a little” isn’t okay.
For families like mine, that would be transformative. The anxiety around cross-contact at restaurants, school events, and travel is constant. An enzyme that could reliably break down trace gluten in the stomach would provide peace of mind that no amount of label-reading currently offers.
Important reality check: This hasn’t been tested in humans yet. The path from impressive lab results to an approved therapy typically takes a decade or more, and many promising candidates fail along the way. This isn’t something you can take tomorrow. But it’s one more piece of evidence that the scientific community is working toward making celiac disease easier to manage.
Key Takeaways
- The enzyme works in your stomach before gluten reaches your intestines
- Lab tests showed it broke down 99% of harmful gluten fragments
- It’s engineered to survive stomach acid and work alongside your body’s natural digestive enzymes
- This isn’t a cure—it wouldn’t let you eat regular pizza—but could protect against accidental exposure
- Human trials haven’t started yet; any treatment is years away
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
What Makes Celiacase Different
The researchers engineered celiacase from neprosin (an enzyme found in pitcher plants) specifically to address the challenges that have limited previous enzyme candidates. They optimized it for maximal activity at gastric pH—the acidic environment of the stomach—and engineered it to resist degradation by pepsin (the stomach’s own protein-digesting enzyme). In fact, celiacase works synergistically with pepsin rather than competing with it.
This is critical. Earlier enzyme candidates, including the Aspergillus niger prolyl endopeptidase (a fungal enzyme that breaks specific protein bonds), often struggled to remain active in the harsh gastric environment. Celiacase was designed from the ground up to thrive there.
The enzyme targets the 33-mer peptide—a notorious gluten fragment containing 33 amino acids that resists normal human digestive enzymes and triggers immune responses in celiac patients. In head-to-head comparisons with the Aspergillus niger enzyme, celiacase outperformed in degrading gluten immunogenic peptides (the specific protein fragments from gluten that trigger the autoimmune response) from both wheat flour and purified gliadin (the main protein component of gluten).
Lab Tests and Animal Models Show Strong Results
The research team tested celiacase in a dynamic human gastrointestinal simulator (a lab device that mimics stomach and intestinal conditions more accurately than static test-tube experiments). At an enzyme-to-gliadin ratio of 1:250, celiacase reduced gluten immunogenic peptide levels by up to 99%. That’s a remarkable level of degradation.
In ex vivo experiments (tests using tissue samples from actual patients outside the body), the researchers used duodenal biopsies (small tissue samples from the first part of the small intestine) from celiac patients. Gluten fragments digested by celiacase failed to trigger cytokine responses—the inflammatory chemical signals that drive intestinal damage in celiac disease. The enzyme-treated gluten essentially became immunologically inert.
In mouse models fed gliadin, low-dose celiacase (at ratios as conservative as 1:75 to 1:380) degraded gliadin and reduced multiple markers of celiac pathology: villus atrophy (flattening of the finger-like projections that absorb nutrients), intestinal inflammation, antibody responses, and gluten-induced dysbiosis (imbalance in gut bacteria). The enzyme also helped restore immune-regulatory markers and microbial metabolic pathways that had been disrupted by gluten exposure.
These are the kinds of results that make enzyme therapy feel less like science fiction and more like something that could actually reach patients. Earlier this year we covered promising findings on enzyme therapies and immune tolerance approaches, and celiacase represents a concrete example of how far this field has advanced.
Intended Use: Supplement, Not Replacement
The researchers describe celiacase as “a potent, acid-stable glutenase” (gluten-digesting enzyme) “with promise as a therapeutic adjunct or alternative to a gluten-free diet.” That phrase “alternative to a gluten-free diet” needs careful interpretation.
The study suggests the enzyme could serve as an adjunct therapy—a supplement to the gluten-free diet that provides protection against accidental exposure. The study also raises the possibility—still theoretical—that a sufficiently effective enzyme could allow some degree of intentional gluten consumption in controlled settings. That’s speculative and would require extensive human trials and regulatory scrutiny before becoming reality.
The Long Road from Lab to Patient
It’s worth tempering excitement with realism. Celiacase has shown impressive results in lab models and animal studies, but it has not yet been tested in human clinical trials (studies testing safety and effectiveness in people). The path from a promising preclinical candidate (a treatment that works in the lab) to an approved therapy is long, expensive, and uncertain. Many drug candidates that look excellent in animal models fail to perform as well in humans, or reveal unforeseen safety concerns.
Additionally, enzyme therapies are not cures. Even if celiacase proves safe and effective in human trials, it would not reverse the autoimmune process of celiac disease or repair existing intestinal damage. It would be a management tool, not a disease-modifying treatment (one that changes the underlying disease process).
That said, management tools matter enormously. The gluten-free diet is effective at inducing mucosal healing (repair of the intestinal lining) and preventing symptoms, but it’s also burdensome, expensive, and socially isolating. Any therapy that reduces the burden of the diet—even modestly—would improve quality of life for celiac patients and their families.
Building on Prior Work
This research builds on a growing body of work exploring enzymatic breakdown of gluten as a therapeutic strategy. We’ve previously reported on molecular discoveries that could neutralize gluten and experimental drugs offering new treatment hope. Celiacase represents the next iteration of this approach: not just identifying enzymes that can degrade gluten in principle, but engineering them specifically for optimal performance in the human digestive system.
The engineering aspect is what sets this work apart. The researchers didn’t simply screen natural enzymes for gluten-degrading activity; they systematically modified a plant enzyme to enhance its expression (how efficiently cells produce the enzyme), stability, and activity under gastric conditions. That level of precision suggests a maturation of the field—a shift from proof-of-concept experiments (tests showing an idea could work) to purposeful drug design.
What Comes Next
The next step is human trials. If celiacase moves forward into Phase I and Phase II studies (early-stage clinical trials testing safety and dosing in humans), researchers will need to answer critical questions: Is it safe? Does it degrade gluten as effectively in living humans as it does in lab simulations? What dose is required? How should it be administered—as a pill taken before meals, or in some other formulation? And most importantly, does it actually reduce symptoms and intestinal damage in celiac patients exposed to gluten?
Those studies will take years. But for celiac families who have been living with dietary restrictions as the only available treatment, the fact that this research exists—that serious scientists are engineering enzymes specifically to protect celiac patients from gluten—is itself meaningful.
I want my son to grow up in a world where his celiac disease is manageable without constant anxiety. A world where eating out doesn’t require a risk assessment, where birthday parties don’t require advance logistics, where a mistake doesn’t mean days of abdominal pain and weeks of intestinal inflammation. Celiacase won’t deliver that world tomorrow, or even next year. But it’s one more piece of evidence that the scientific community is working toward it.
Related Coverage
- Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
- A breakthrough molecular discovery could neutralize gluten and protect coeliac patients
- Experimental drug offers new hope for celiac disease treatment
References
Girbal-González, M., Rodríguez-Banqueri, A., Swaid, H., Mendes, S. R., Garzón-Flores, L., Ramírez-Larrota, J. S., Cueva, C., Moreno-Arribas, M. V., Regl, C., Huber, C. G., Scherf, K. A., Rodríguez-Lagunas, M. J., Franch-Masferrer, À., Eckhard, U., Pérez-Cano, F. J., & Gomis-Rüth, F. X. (2026). Targeted enzymatic therapy for coeliac disease. EMBO Molecular Medicine. Advance online publication. https://doi.org/10.1038/s44321-026-00430-8